amoxapine

Trade name: asendin

Small moleculeapproved

Approved

Sep 22, 1980

Amoxapine is an antidepressant of the dibenzoxazepine class, chemically distinct from the dibenzazepines, dibenzocycloheptenes, and dibenzoxepines. It is designated chemically as 2-Chloro-11- (1-piperazinyl)dibenz[b,f ][1,4]oxazepine. Amoxapine is an antidepressant with a mild sedative component to its action. The mechanism of its clinical action in man is not well understood. In animals, amoxapine reduced the uptake of norepinephrine and serotonin and blocked the response of dopamine receptors to dopamine. Amoxapine is not a monoamine oxidase inhibitor. Amoxapine is absorbed rapidly and reaches peak blood levels approximately 90 minutes after ingestion. It is almost completely metabolized. The main route of excretion is the kidney. In vitro tests show that amoxapine binding to human serum is approximately 90%. In man, amoxapine serum concentration declines with a half-life of eight hours. However, the major metabolite, 8-hydroxyamoxapine, has a biologic half-life of 30 hours. Metabolites are excreted in the urine in conjugated form as glucuronides. Clinical studies have demonstrated that amoxapine has a more rapid onset of action than either amitriptyline or imipramine. The initial clinical effect may occur within four to seven days and occurs within two weeks in over 80% of responders. — NCATS

Clinical trial activity

0 trials · 0 clinical orgs · 5 marketing orgs

Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0

Timeline

1980s

  1. Sep 22, 1980

    Lederle — Earliest FDA Approval

  2. Sep 22, 1980

    Lederle — NDA Secondary Org

  3. Sep 22, 1980

    Lederle — NDA Organization

  4. Sep 22, 1980

    American Cyanamid — NDA Secondary Org

1990s

  1. Jun 28, 1991

    Upsher-Smith Laboratories — Marketing Organization

  2. Jun 28, 1991

    Chartwell Pharmaceuticals — Marketing Organization

  3. Aug 28, 1992

    Watson Pharmaceuticals — Marketing Organization

Indications

Mechanism of action

Approval history

  • approvedSep 22, 1980

Chemistry & pharmacology

Loading structure…

SMILES

ClC1=CC=C2OC3=CC=CC=C3N=C(N4CCNCC4)C2=C1
Mol. weight
313.781 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Delivery
Oral
Availability
Prescription Only

Oral

Yes

Parenteral

No

Topical

No

Black box warning

Sources

Also known as

  • 2-chloro-11-(1-piperazinyl)dibenz(b,f)(1,4)oxazepine
  • 2-chloro-11-(1-piperazinyl)dibenz(b,f)(1,4)oxazepine
  • amoxan
  • amoxapin
  • amoxapin
  • amoxapina
  • amoxapina
  • amoxapine
  • amoxapine
  • amoxapine
  • amoxapine
  • amoxapine
  • amoxapine
  • amoxapine
  • amoxapine
  • amoxapine
  • amoxapine
  • amoxapinum
  • amoxapinum
  • amoxepine
  • amoxepine
  • asendin
  • asendin
  • asendin
  • asendis
  • asendis
  • cl-67772
  • cl-67772
  • defanyl
  • defanyl
  • desmethylloxapin
  • desmethylloxapin
  • desmethylloxapine
  • moxadil

Organizations

Marketing (7)

OrganizationOrg typeRelationshipDate
American CyanamidFor profitNDA2Sep 22, 1980
Chartwell PharmaceuticalsFor profitMKTGJun 28, 1991
LederleFor profitNDA2Sep 22, 1980
LederleFor profitNDASep 22, 1980
Upsher-Smith LaboratoriesFor profitMKTGJun 28, 1991
Watson PharmaceuticalsFor profitMKTGAug 28, 1992
Watson PharmaceuticalsFor profitSYNMay 11, 1989